| Keywords: |
adult; child; clinical article; controlled study; preschool child; school child; aged; aged, 80 and over; middle aged; unclassified drug; gene mutation; overall survival; allogeneic stem cell transplantation; neutropenia; hepatitis; outcome assessment; antineoplastic agent; letter; infection; antimetabolites, antineoplastic; blood toxicity; thrombocytopenia; clinical assessment; cohort analysis; drug effect; dna methylation; febrile neutropenia; hospitalization; graft failure; hematologic malignancy; myelodysplastic syndrome; death; tumor protein; hospital admission; hematopoietic stem cell; neoplasms, second primary; drug therapy; immunosuppressive treatment; antineoplastic antimetabolite; cytopenia; brain hemorrhage; cyclosporine; azacitidine; myelodysplastic syndromes; paroxysmal nocturnal hemoglobinuria; thymocyte antibody; aplastic anemia; dysplasia; transcription factor runx1; dna methyltransferase 3a; etiology; acute myeloid leukemia; anemia, aplastic; clonal hematopoiesis; Common Terminology Criteria for Adverse Events; hypomethylating agent; international prognostic scoring system; asxl1 protein; disease burden; very elderly; humans; human; male; female; venetoclax; clonal hematopoiesis of indeterminate potential; alloimmunization; second primary neoplasm; acquired aplastic anemia; secondary myeloid neoplasm
|
